search

Active clinical trials for "Neoplasms"

Results 3021-3030 of 64586

Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

LeukemiaMyelodysplastic Syndromes11 more

RATIONALE: Giving chemotherapy, such as busulfan, fludarabine, and melphalan, before a donor umbilical cord blood stem cell transplant helps stop the growth of abnormal or cancer cells and prepares the patient's bone marrow for the stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil may stop this from happening. PURPOSE: This phase II trial is studying how well combination chemotherapy followed by a donor umbilical cord blood transplant works in treating infants with high-risk acute leukemia or myelodysplastic syndromes.

Recruiting21 enrollment criteria

rRp450-Phase I Trial in Liver Metastases and Primary Liver Tumors

Liver MetastasesPrimary Liver Cancers

The purpose of this research study is to determine the safety of rRp450 and the highest dose of this agent that can be given to people safely. We are also looking to see how well the body tolerates the study agent, how the agent is absorbed by the liver cancers, how quickly the agent is eliminated from the body, and what kind of anti-cancer effect it may have. rRp450 is a type of gene therapy and a form of the Herpes simplex virus 1 (or HSV). HSV is a virus that usually causes cold sores of the mouth. In extremely rare circumstances, this virus can cause severe infections, such as an infection of the brain. rRp450 was developed from an HSV and specially altered to target and kill cancer cells.

Recruiting21 enrollment criteria

Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression...

Neuroendocrine TumorsProgesterone Receptor Positive Tumor1 more

This is a single-arm, single-stage clinical study of tamoxifen for patients with well-differentiated neuroendocrine tumors and radiological progression with positive (> 1%) HR (estrogen and/or progesterone) expression by immunohistochemistry (IHC).

Recruiting29 enrollment criteria

Study of SRF114 in Patients With Advanced Solid Tumors

Advanced Solid TumorHead and Neck Squamous Cell Carcinoma

This is a Phase 1/2, open-label, first-in-human, dose-escalation and expansion study of SRF114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.

Recruiting27 enrollment criteria

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small...

Non-small Cell Lung CancerMetastatic Non-small Cell Lung Cancer

The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (< 50%).

Recruiting11 enrollment criteria

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

SCLC,Extensive Stage

This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.

Recruiting42 enrollment criteria

Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma...

Primary Central Nervous System Lymphoma

It is a single arm, multicenter, phase 2 study to explore the efficacy and safety study of OR-MTX chemotherapy(Orelabrutinib, Rituximab and Methotrexate)as first-line regimens in the treatment of newly diagnosed primary central nervous system lymphoma. Objective response rate is the primary endpoint.

Recruiting31 enrollment criteria

A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA

Unresectable Angiosarcoma

The purpose of the study is to investigate efficacy and safety Boron Neutron Capture Therapy (BNCT) by using CICS-1 accelerator-based neutron capture therapy device with lithium targets developed by CICS, and the SPM-011 boron compound for use in BNCT developed by STELLA PHARMA in the treatment of unresectable angiosarcoma.

Recruiting8 enrollment criteria

Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2

Salivary Gland Tumors

The goal of this clinical trial is to learn about the efficacy and safety of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic salivary cancer.

Recruiting33 enrollment criteria

Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

AMLAdult

This is an open-label, Phase I study of QN-023a (allogeneic CAR-NK cells targeting CD33) in relapsed/refractory Acute Myeloid Leukemia (AML). The clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-023a in patients with relapsed/refractory AML,where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 18 patients will be enrolled.

Recruiting20 enrollment criteria
1...302303304...6459

Need Help? Contact our team!


We'll reach out to this number within 24 hrs